Corteva, Inc. (NYSE:CTVA) Receives $90.19 Consensus PT from Brokerages

Corteva, Inc. (NYSE:CTVA) has been assigned an average recommendation of “Moderate Buy” from the twenty-two analysts that are covering the firm, Marketbeat.com reports. Eight investment analysts have rated the stock with a hold recommendation, thirteen have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month price target among brokerages that have updated their coverage on the stock in the last year is $90.1905.

A number of brokerages have weighed in on CTVA. Jefferies Financial Group raised their price objective on Corteva from $95.00 to $97.00 in a research note on Thursday, May 7th. Barclays upped their target price on Corteva from $84.00 to $91.00 and gave the company an “overweight” rating in a research report on Thursday, June 11th. Bank of America raised their price target on shares of Corteva from $90.00 to $96.00 and gave the stock a “buy” rating in a research report on Monday, July 20th. Mizuho lifted their price target on shares of Corteva from $96.00 to $97.00 and gave the stock an “outperform” rating in a research note on Tuesday, July 14th. Finally, UBS Group cut their price target on shares of Corteva from $90.00 to $86.00 and set a “neutral” rating on the stock in a report on Tuesday, June 9th.

Trending Headlines about Corteva

Here are the key news stories impacting Corteva this week:

• Positive Sentiment: Corteva reported second-quarter adjusted EPS of $2.30, exceeding the $2.24 analyst consensus and rising from $2.20 a year earlier. Seed pricing, productivity improvements, demand for newer genetics and traits, and growth in Crop Protection products supported margins. Reuters earnings report
• Positive Sentiment: The company raised its fiscal 2026 EPS outlook to $3.60-$3.80, reflecting strong first-half performance, operating improvements and growth platforms. Management also said it remains on track for the planned October 1 Vylor spin-off, a potential catalyst for improved business focus and valuation. Corteva first-half results and outlook
• Positive Sentiment: Analyst commentary remains broadly constructive: Corteva has outperformed the broader market and agriculture-focused ETFs, while brokerages maintain a consensus “Moderate Buy” rating. Momentum-focused analysis also highlights the company’s improving execution and fundamentals. Brokerage consensus rating
• Neutral Sentiment: Despite the earnings beat and higher guidance, one analysis argues that much of Corteva’s improved execution is already reflected in the stock, leaving limited upside unless earnings growth accelerates. Corteva valuation analysis
• Negative Sentiment: Second-quarter revenue was $6.38 billion, below the $6.60 billion consensus and down 1.2% year over year. The sales miss, together with competitive pricing pressure, appears to be the main reason the stock moved lower despite the profit beat and raised outlook. Corteva second-quarter earnings summary

Institutional Trading of Corteva

Several hedge funds and other institutional investors have recently bought and sold shares of CTVA. Tema ETFs LLC lifted its holdings in Corteva by 10.4% during the 2nd quarter. Tema ETFs LLC now owns 10,774 shares of the company’s stock worth $912,000 after buying an additional 1,015 shares during the last quarter. City Holding Co. raised its position in shares of Corteva by 2.6% during the 2nd quarter. City Holding Co. now owns 25,086 shares of the company’s stock valued at $2,124,000 after acquiring an additional 635 shares in the last quarter. Sax Wealth Advisors LLC acquired a new stake in shares of Corteva during the 2nd quarter valued at approximately $237,000. Avity Investment Management Inc. lifted its stake in Corteva by 14.4% during the second quarter. Avity Investment Management Inc. now owns 5,172 shares of the company’s stock worth $438,000 after purchasing an additional 650 shares during the last quarter. Finally, Valeo Financial Advisors LLC lifted its stake in Corteva by 8.3% during the second quarter. Valeo Financial Advisors LLC now owns 6,963 shares of the company’s stock worth $589,000 after purchasing an additional 536 shares during the last quarter. 81.54% of the stock is owned by institutional investors.

Corteva Stock Performance

Shares of CTVA stock opened at $78.98 on Friday. The company has a debt-to-equity ratio of 0.07, a current ratio of 1.52 and a quick ratio of 1.10. The company’s fifty day moving average price is $82.15 and its two-hundred day moving average price is $79.63. The firm has a market capitalization of $52.83 billion, a P/E ratio of 52.31, a P/E/G ratio of 2.39 and a beta of 0.57. Corteva has a 12 month low of $60.53 and a 12 month high of $90.97.

Corteva (NYSE:CTVA) last announced its earnings results on Thursday, July 30th. The company reported $2.30 earnings per share for the quarter, beating the consensus estimate of $2.24 by $0.06. Corteva had a return on equity of 10.18% and a net margin of 5.66%.The company had revenue of $6.38 billion during the quarter, compared to the consensus estimate of $6.60 billion. During the same period last year, the firm earned $2.20 earnings per share. The company’s revenue was down 1.2% on a year-over-year basis. Corteva has set its FY 2026 guidance at 3.600-3.800 EPS. On average, research analysts anticipate that Corteva will post 3.75 earnings per share for the current fiscal year.

Corteva Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 15th. Stockholders of record on Tuesday, September 1st will be paid a $0.18 dividend. This represents a $0.72 dividend on an annualized basis and a dividend yield of 0.9%. The ex-dividend date is Tuesday, September 1st. Corteva’s dividend payout ratio is 47.68%.

About Corteva

Corteva, Inc (NYSE: CTVA) is an independent global agriculture company that was established as a publicly traded firm in mid‑2019 following the separation of the agriculture businesses from DowDuPont. The company focuses on delivering technologies and products that help farmers increase productivity and manage crop health. Corteva’s operations combine seed genetics, crop protection chemistries, digital tools and biological solutions to address the full cycle of crop production.

Core business activities include research and development of seed genetics and trait technologies, formulation and sale of crop protection products (such as herbicides, insecticides and fungicides), and the development of seed treatments and biologicals.